Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (31)
- Cosmetics (4)
- COVID-19 (11)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (42)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (3)
- Vaping hub (5)
- Weight loss products (1)
Search
311 result(s) found, displaying 201 to 225
-
GuidanceGuidance to understand how we interpret regulations and how manufacturers can comply with them.
-
GuidanceThis guidance describes the requirements for manufacturers and sponsors of faecal microbial transplant (FMT) products in TGO 105.
-
GuidanceGuidance on how exempt disinfectants are defined and meeting the regulatory requirements for their manufacture, supply and advertising.
-
GuidanceGuidance to help you understand which therapeutic goods will be regulated as a biological.
-
GuidanceGuidance updated to reflect expectations of the new PIC/S guide to GMP PE009-13.
-
GuidanceGuidance for sponsors of COVID-19 IVDs about their ongoing obligations
-
GuidanceHow to meet regulatory requirements for the manufacture and supply of menstrual cups in Australia.
-
GuidanceGuidance to assist sponsors and manufacturers in preparing their documentation for applications for COVID-19 rapid antigen tests.
-
GuidanceThis guidance provides information about preparing Consumer Medicine Information (CMI) documents that comply with current regulations.
-
GuidanceGuidance for the requirements applicable to medical devices containing poisons.
-
GuidanceGuidance to determine the level of regulation of PRP, PRF or conditioned serum products for therapeutic use.
-
GuidanceThis guidance helps providers of digital mental health services or products to understand their regulatory obligations.
-
GuidanceGuidance for sponsors and manufacturers on regulatory responsibilities associated with first aid kits supplied using the special Conformity Assessment procedure.
-
GuidanceGuidance for sponsors and manufacturers about pathways for exporting a ventilator from Australia.
-
GuidanceGuidance on the priority applicant determination criteria and process for medical devices including in vitro diagnostics (IVDs).
-
GuidanceGuidance to help manufacturers of active medical devices, including software-based medical devices, to classify their devices.
-
GuidanceGuidance on mandatory warning statements for labels of medicines containing neuromuscular blocking agents.
-
GuidanceGuidance to assist sponsors with the reclassification of surgical mesh devices.
-
GuidanceGuidance on generic and originator medicines in the context of over-the-counter (OTC) non-prescription medicine applications.
-
GuidanceGuidance for manufacturers and sponsors on the product standards that apply to haematopoietic progenitor cells (HPCs).
-
GuidanceGuidance about the Annual Charge Exemption (ACE) scheme waiver process.
-
GuidanceGuidance on the application of the Therapeutic Goods (Vaping Goods - Possession and Supply) Determination 2024.
-
GuidanceGuidance for sponsors on the eligibility criteria for reduced application and evaluation fees for major variation applications for prescription medicines.
-
GuidanceGuidance for sponsors and manufacturers about medical device definitions and requirements for system or procedure packs.
-
GuidanceThis guidance applies to manufacturers of medical devices that are regulated as system or procedure packs and supplied using the special conformity assessment procedure regulatory pathway.